CardiaTec closed $6.5M Seed round

CardiaTec, a TechBio company, secured $6.5 million in seed funding. The round was led by Montage Ventures with participation from Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures. Individual investors Dr. Maximilien Levesque and Naheed Kurji also participated in the round.

CardiaTec employs computational methods to decode the biology behind cardiovascular disease. The company leverages large multi-omics human data to identify novel and more targeted therapeutics. The new funds will be used to expand its platform and progress proprietary drug targets to wet lab validation. CardiaTec is building a proprietary human heart tissue multi-omics dataset and has a network of over 65 hospitals across the US and UK to support data generation.